• Arts
  • Language Services
  • Furniture
  • Educational Services
  • Private Equity
  • Event Management
  • Nonprofit / Foundation
  • Manufacturing
  • Information Technology
  • Human Resources
  • Hotels and Restaurants
  • Health Care & Pharmaceuticals
  • Media - Broadcast and Publishing
  • Engineering / Construction
  • Food Products, Beverages and Tobacco
  • Petroleum Industry
  • Wholesale and Retail Trade
  • Travel and Leisure
  • Transporting, Moving and Warehousing
  • Telecommunications
  • Security Services
  • Real Estate
  • Marketing and Public Relations
  • Energy
  • Finance
  • Consumer Goods
  • Law Companies
  • Consultancy
  • Architecture
  • Airlines

News

Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program

8.11.2017
Company: AMGEN, s.r.o.

Parties to Collaborate on a New Generation Study 2, Assessing Whether Investigational Drug CNP520 Can Prevent or Delay the Symptoms of Alzheimer's Disease
Clinical Trial is Part of the Generation Program, Which Includes Cognitively Healthy People at Genetic Risk of Developing Alzheimer's Disease
Generation Study 2 Aims to Include a Broader High-Risk Population, as Compared to the Ongoing Generation Study 1
44 Million People Globally are Estimated to Have Alzheimer's Disease or a Related Dementia, With One New Case Diagnosed Every Three Seconds(1,2)

Amgen (NASDAQ:AMGN) and Novartis today announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial – the Alzheimer's Prevention Initiative (API) Generation Study 2. This trial follows the launch of the Generation Study 1, and will determine whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease symptoms in a high-risk population. BACE1 is an enzyme that plays an important role in the production of Amyloid β, a protein which accumulates in the brains of individuals with Alzheimer's disease years before clinical symptoms begin. More information on the sites participating in Generation Study 2 can be found at ClinicalTrials.gov and in the website www.GenerationProgram.com.

"As a leader in the challenging fight to unlock the biology of serious illnesses like Alzheimer's disease, we are pleased to support the launch of the Generation Study 2 with our partners at Novartis and Banner Alzheimer's Institute to further explore promising potential therapeutic options for this highly debilitating disease," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Through the unique combination of genetic testing and counseling in cognitively healthy adults, the Generation Study 2 exhibits an innovative clinical approach that may offer insight towards Alzheimer's prevention for those at highest risk for developing the disease."

More information here.

Tags: Health |

AmCham Corporate Patrons

x
x

Delete

Are you sure? Do you really want to delete this item?